These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29210656)

  • 1. Editorial: Arterial Stiffness, Central Haemodynamics and Non-Alcoholic Fatty Liver Disease: Links with Cardiovascular Risk and Effects of Drug Treatment.
    Katsiki N; Imprialos K; Vlachopoulos C
    Curr Vasc Pharmacol; 2018; 16(4):401-404. PubMed ID: 29210656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension.
    Mitsiou E; Boutari C; Kotsis V; Georgianou E; Doumas M; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2018; 16(4):393-400. PubMed ID: 28669329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension.
    Catena C; Bernardi S; Sabato N; Grillo A; Ermani M; Sechi LA; Fabris B; Carretta R; Fallo F
    Nutr Metab Cardiovasc Dis; 2013 Apr; 23(4):389-93. PubMed ID: 22796347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms?
    Villela-Nogueira CA; Leite NC; Cardoso CR; Salles GF
    Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27104526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease is associated with progression of arterial stiffness.
    Li N; Zhang GW; Zhang JR; Jin D; Li Y; Liu T; Wang RT
    Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):218-23. PubMed ID: 25456154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease associated with increased arterial stiffness in subjects with normal glucose tolerance, but not pre-diabetes and diabetes.
    Chou CY; Yang YC; Wu JS; Sun ZJ; Lu FH; Chang CJ
    Diab Vasc Dis Res; 2015 Sep; 12(5):359-65. PubMed ID: 26008803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Jaruvongvanich V; Chenbhanich J; Sanguankeo A; Rattanawong P; Wijarnpreecha K; Upala S
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):e28-e35. PubMed ID: 28542113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness.
    Sunbul M; Agirbasli M; Durmus E; Kivrak T; Akin H; Aydin Y; Ergelen R; Yilmaz Y
    Atherosclerosis; 2014 Dec; 237(2):490-3. PubMed ID: 25463079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics.
    Koumaras C; Tzimou M; Stavrinou E; Griva T; Gossios TD; Katsiki N; Athyros VG; Mikhailidis DP; Karagiannis A
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):143-56. PubMed ID: 22540323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?
    Oni ET; Agatston AS; Blaha MJ; Fialkow J; Cury R; Sposito A; Erbel R; Blankstein R; Feldman T; Al-Mallah MH; Santos RD; Budoff MJ; Nasir K
    Atherosclerosis; 2013 Oct; 230(2):258-67. PubMed ID: 24075754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
    Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
    Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased whole blood viscosity associated with arterial stiffness in patients with non-alcoholic fatty liver disease.
    Yu KJ; Zhang MJ; Li Y; Wang RT
    J Gastroenterol Hepatol; 2014 Mar; 29(3):540-4. PubMed ID: 23981121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
    Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease and cardiovascular risk in children with obesity.
    Koot BG; de Groot E; van der Baan-Slootweg OH; Bohte AE; Nederveen AJ; Jansen PL; Stoker J; Benninga MA
    Obesity (Silver Spring); 2015 Jun; 23(6):1239-43. PubMed ID: 25960049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease prevention strategies for type 2 diabetes mellitus.
    Katsiki N; Purrello F; Tsioufis C; Mikhailidis DP
    Expert Opin Pharmacother; 2017 Aug; 18(12):1243-1260. PubMed ID: 28685623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease.
    Brea Á; Pintó X; Ascaso JF; Blasco M; Díaz Á; González-Santos P; Hernández Mijares A; Mantilla T; Millán J; Pedro-Botet J;
    Clin Investig Arterioscler; 2017; 29(3):141-148. PubMed ID: 27692633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up.
    Fracanzani AL; Tiraboschi S; Pisano G; Consonni D; Baragetti A; Bertelli C; Norata D; Valenti L; Grigore L; Porzio M; Catapano A; Fargion S
    Atherosclerosis; 2016 Mar; 246():208-13. PubMed ID: 26803429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.